Highlights from ASCO Annual Meeting 2024

Meeting Mic

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.

Joseph A. Greer, PhD, discusses how early palliative care via telehealth had an equivalent impact on quality of life as in-person visits for patients with advanced non-small cell lung cancer. :27

Charu Aggarwal, MD, MPH, FASCO, further discusses these findings during a press briefing. 3:30

Heinz-Josef Lenz, MD, shares his thoughts on the first-line immunotherapy combination of nivolumab and ipilimumab in colorectal cancer. 4:35

Fumiko Chino, MD, discusses findings on the need for a more effective and transparent prior authorization process to ensure patients receive timely access to essential pain management. 7:09

Suneel Kamath, MD, provides an overview of findings assessing how the microbiome profile of early-onset pancreatic adenocarcinoma is distinct from that of average-onset disease. 10:22

Julie R. Gralow, MD, FACP, FASCO, discusses the important implications of a prospective study on young breast cancer survivors who attempted pregnancy and became pregnant. 12:54

Read the full coverage here:

https://www.healio.com/news/hematology-oncology/20240602/we-have-the-technology-telehealth-increases-access-to-palliative-care-for-cancer

https://www.healio.com/news/hematology-oncology/20240602/practicechanging-data-support-firstline-immunotherapy-combination-in-colorectal-cancer

https://www.healio.com/news/hematology-oncology/20240531/findings-highlight-need-to-improve-prior-authorization-process-for-cancer-pain-management

https://www.healio.com/news/hematology-oncology/20240603/tumor-microbiome-profiles-in-pancreatic-cancer-differ-by-age-of-onset

https://www.healio.com/news/hematology-oncology/20220611/intramuscular-recombinant-erwinia-asparaginase-active-safe-in-leukemia-lymphoma-subsets

Glucose-lowering drugs reduce risk for obesity-related cancers

Source: Lin CH, et al. Abstract 10508. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago.

Chemotherapy regimen improves survival in advanced esophageal cancer

Source: Hoeppner J, et al. Abstract LBA1. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago.

Disclosures:

Chino reports no relevant financial disclosures.

Greer reports a consulting role with BeiGene; research funding from Blue Note Therapeutics and NCCN/AstraZeneca; and royalties from Oxford University Press and Springer Publishing Company. Please see the abstract for all other researchers’ relevant financial disclosures.[JJ1]

Kamath reports no relevant financial disclosures.

Lenz reports honoraria from, consulting/advisory roles with, or travel, accommodations or expenses from 3T Biosciences, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Fulgent Genetics, G1 Therapeutics, GSK, Isofol Medical, Jazz Pharmaceuticals, Merck Serono, Oncocyte and Roche. Please see the abstract for all other researchers’ relevant financial disclosures.